Sutro Biopharma, Inc.

NASDAQ:STRO

4.12 (USD) • At close September 6, 2024
Bedrijfsnaam Sutro Biopharma, Inc.
Symbool STRO
Munteenheid USD
Prijs 4.12
Beurswaarde 337,690,444
Dividendpercentage 0%
52-weken bereik 2.01 - 6.13
Industrie Biotechnology
Sector Healthcare
CEO Mr. William J. Newell J.D.
Website https://www.sutrobio.com

An error occurred while fetching data.

Over Sutro Biopharma, Inc.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for

Vergelijkbare Aandelen

PepGen Inc. logo

PepGen Inc.

PEPG

8.83 USD

Singular Genomics Systems, Inc. logo

Singular Genomics Systems, Inc.

OMIC

5.892 USD

Alpha Teknova, Inc. logo

Alpha Teknova, Inc.

TKNO

4.59 USD

Nuvectis Pharma, Inc. logo

Nuvectis Pharma, Inc.

NVCT

6.18 USD

bluebird bio, Inc. logo

bluebird bio, Inc.

BLUE

0.529 USD

Prelude Therapeutics Incorporated logo

Prelude Therapeutics Incorporated

PRLD

4.85 USD

Kamada Ltd. logo

Kamada Ltd.

KMDA

4.23 USD

VistaGen Therapeutics, Inc. logo

VistaGen Therapeutics, Inc.

VTGN

3.25 USD

Altimmune, Inc. logo

Altimmune, Inc.

ALT

6.2 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)